Eszopiclone

CHEMBL1522 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

388.8 g/mol

LogP

0.5

Phase

4

This non-benzodiazepine sleep medication works by enhancing GABA activity in the brain to help people fall asleep and stay asleep through the night. It is approved for the longer-term treatment of insomnia.

Moleküler Ağırlık

388,8000 g/mol

LogP

0,50

TPSA

91,80 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Parkinson's Disease Migraine Schizophrenia Generalized Anxiety Disorder Insomnia Multiple Sclerosis Type 2 Diabetes Hypertension Major Depressive Disorder

Etki Mekanizması

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1

InChI

InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1

Molecular Formula

C17H17ClN6O3

HBD / HBA

- / 7

Döndürülebilir Bağlar

3

Ağır Atomlar

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This non-benzodiazepine sleep medication works by enhancing GABA activity in the brain to help people fall asleep and stay asleep through the night. It is approved for the longer-term treatment of insomnia.

Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.

Yes, Eszopiclone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1522. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 969472. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Eszopiclone PillFYI'da

Yapı

Hızlı Veriler

Formül: C17H17ClN6O3
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.